Global Microbiome Therapeutics (Fungi, Bacteria, Bacteriophage, Viruses, and Protozoa) Markets, 2019-2020 & 2030: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Global Microbiome Therapeutics Market to Reach $3.9 Billion by 2030

Clinical studies on various microbiomes have been significantly growing during the past decade, owing to the considerable reduction in the cost of DNA sequencing, enabling the microbes in their complex mixture to be defined by their genome. Research findings have generated information about the role of the microorganism population in determining human health.

The microbiome is found to play a role in inflammatory bowel disease (IBD), allergies, and immune-oncology, among others. Microbiomes have become an attractive target for potential therapeutics owing to its extensive role in gastrointestinal and non-gastrointestinal diseases.

However, there are challenges associated with microbiome research. Determining the cause-effect relationships and designing microbiome-based therapies that can attain effective results on the human health and microbial community are among such challenges.

Several players, such as Sanofi S.A and Taisho Pharmaceuticals, are currently offering these microbiome therapeutics in the market. The entry of new players in the market, coupled with increased innovation pertaining to therapeutic output maximization with minimal side effects, has transformed the market currently.

The existing market of microbiome therapeutics is favored by multiple factors, which include the rising geriatric populations coupled with the increased financing and the increasing adoption of inorganic growth strategies by key players in the market.

Within the research report, the market is segmented on the basis of target therapy area (gastrointestinal and infectious diseases, and other diseases) and region (North America, Europe, Asia-Pacific, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players, including 4D Pharma, Enterome, and Finch Therapeutics, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, Asia-Pacific is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with soaring clinical activities pertaining to the development of microbiome therapeutics.

Key Topics Covered:

1 Product Definition

1.1 Inclusion and Exclusion

2 Market Scope

2.1 Scope of Work

2.2 Key Questions Answered in the Report

3 Research Methodology

3.1 Global Microbiome Therapeutics Market: Research Methodology

3.2 Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

4 Market Overview

4.1 Market Size and Future Growth Potential

4.2 Historical Trends

5 Industry Insights

5.1 Regulatory Landscape

5.1.1 Regulatory Requirements for Live Biotherapeutic Products (LBPs)

5.2 Patent Landscape

5.2.1 Patent Filing Analysis

5.2.2 Key Players Patent Portfolio

5.2.3 Key Players Patent Expiration Analysis

5.3 Financing Landscape

5.3.1 Financing Stratification (as Per Raised Financing Value)

5.3.2 Year on Year Financing Analysis (FY2017-3Q2020)

5.3.3 Investment Heat Map

5.4 Pipeline Landscape

5.4.1 Competitive Landscaping

5.4.2 Pipeline Analysis

5.4.2.1 By Developmental Phase

5.4.2.2 By Route of Administration

5.4.2.3 By Type of Microbiome Strategy

5.4.2.4 By Target Therapy Area

5.5 Partnership Landscape

5.6 Government Initiatives

6 Market Dynamics

6.1 Market Drivers

6.1.1 Significant External Funding for Executing Research and Therapeutic Innovation

6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market

6.2 Market Restraints

6.2.1 Payer Uncertainty and Outcome-Based Pricing

6.2.2 Insufficient Application-Based Research Hindering Market Pull

6.2.3 FMT Manufacturing Issues

6.3 Market Opportunities

6.3.1 Entry of Major Players for the Development of Microbiome Therapeutics

6.3.2 Growing Eminence of Microbiome Therapeutics in Cancer Treatment

7 Competitive Insights

7.1 Key Strategies and Developments

7.2 Synergistic Activities

7.3 Regulatory Accreditations

7.4 Mergers and Acquisitions

7.5 Market Share Analysis

7.6 Growth Share Analysis (Opportunity Mapping)

7.6.1 By Geography

7.6.2 By Company

8 Global Microbiome Therapeutics Market (by Target Therapy Area)

8.1 Overview

8.2 Gastrointestinal and Infectious Diseases

8.3 Other Diseases

9 Global Microbiome Therapeutics Market (by Region)

9.1 Overview

9.2 North America

9.2.1 Overview

9.2.2 U.S.

9.2.3 Canada

9.3 Europe

9.3.1 Overview

9.3.2 France

9.3.3 Sweden

9.3.4 Germany

9.3.5 U.K.

9.3.6 Rest-of-Europe

9.4 Asia-Pacific (APAC)

9.4.1 Overview

9.4.2 Japan

9.4.3 Australia

9.4.4 China

9.4.5 India

9.4.6 Rest-of-Asia-Pacific

9.5 Rest-of-the-World

9.5.1 Overview

10 Company Profiles

10.1 Company Overview

10.2 Role in Global Microbiome Therapeutics Market

10.3 Financials

10.4 SWOT Analysis

• 4D Pharma plc
• AOBiome
• Ferring Pharmaceuticals
• Finch Therapeutics
• Immuron Limited
• MaaT Pharma
• Naked Biome
• OxThera AB
• Pendulum Therapeutics
• Quorum Innovations
• Sanofi S.A.
• Seres Therapeutics, Inc.
• Synthetic Biologics
• Taisho Pharmaceutical
• Vedanta Biosciences, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/mxnyf6

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900